M
Melissa R. Spears
Researcher at University College London
Publications - 23
Citations - 4035
Melissa R. Spears is an academic researcher from University College London. The author has contributed to research in topics: Prostate cancer & Androgen deprivation therapy. The author has an hindex of 13, co-authored 23 publications receiving 3149 citations.
Papers
More filters
Journal ArticleDOI
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James,Nicholas D. James,Matthew R. Sydes,Noel W. Clarke,Malcolm David Mason,David P. Dearnaley,Melissa R. Spears,Alastair W. S. Ritchie,Chris Parker,J. Martin Russell,Gerhardt Attard,Johann S. de Bono,William Cross,Robert Jones,George N. Thalmann,Claire Amos,David Matheson,Robin Millman,Mymoona Alzouebi,Sharon Beesley,Alison Birtle,Susannah Brock,Richard Cathomas,Prabir Chakraborti,Simon Chowdhury,Audrey Cook,Tony Elliott,Joanna Gale,Stephanie Gibbs,John Graham,J. Hetherington,Robert Hughes,Robert W. Laing,Fiona McKinna,Duncan McLaren,Joe M. O'Sullivan,Omi Parikh,Clive Peedell,Andrew Protheroe,Angus Robinson,Narayanan Srihari,Rajaguru Srinivasan,John Staffurth,Santhanam Sundar,Shaun Tolan,David Tsang,John Wagstaff,Mahesh K.B. Parmar +47 more
TL;DR: Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population of men, and heterogeneity in treatment effect across prespecified subsets was not found.
Journal ArticleDOI
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James,Johann S. de Bono,Melissa R. Spears,Noel W. Clarke,Malcolm David Mason,David P. Dearnaley,Alastair W. S. Ritchie,Claire Amos,Clare Gilson,Robert Jones,David Matheson,Robin Millman,Gerhardt Attard,Simon Chowdhury,William Cross,Silke Gillessen,Chris Parker,J. Martin Russell,Dominik Berthold,Chris Brawley,Fawzi Adab,San Aung,Alison Birtle,Jo Bowen,Susannah Brock,Prabir Chakraborti,C.L. Ferguson,Joanna Gale,Emma Gray,Mohan Hingorani,Peter Hoskin,Jason F. Lester,Zafar Malik,Fiona McKinna,Neil McPhail,Julian Money-Kyrle,Joe M. O'Sullivan,Omi Parikh,Andrew Protheroe,Angus Robinson,Narayanan Srihari,Carys Thomas,John Wagstaff,James D. Wylie,Anjali Zarkar,Mahesh K.B. Parmar,Matthew R. Sydes +46 more
TL;DR: Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure‐free survival than ADT alone.
Journal ArticleDOI
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
Nicholas D. James,Melissa R. Spears,Noel W. Clarke,David P. Dearnaley,Johann S. de Bono,Joanna Gale,J. Hetherington,Peter Hoskin,Robert Jones,Robert W. Laing,Jason F. Lester,Duncan B. McLaren,Chris Parker,Mahesh K. B. Parmar,A.W.S. Ritchie,J. Martin Russell,Räto T. Strebel,George N. Thalmann,Malcolm David Mason,Matthew R. Sydes +19 more
TL;DR: Survival remains disappointing in men presenting with M1 disease who are started on only long-term androgen deprivation therapy (ADT), despite active treatments being available at first failure of ADT.
Journal ArticleDOI
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
Matthew R. Sydes,Melissa R. Spears,Malcolm David Mason,Noel W. Clarke,David P. Dearnaley,J.S. de Bono,Gerhardt Attard,Simon Chowdhury,William Cross,Silke Gillessen,Silke Gillessen,Zafar Malik,Robert Jones,Robert Jones,Chris Parker,Chris Parker,A.W.S. Ritchie,J. M. Russell,J. M. Russell,Robin Millman,David Matheson,Claire Amos,Clare Gilson,A. Birtle,Susannah Brock,L. Capaldi,Prabir Chakraborti,Ananya Choudhury,Ananya Choudhury,L. Evans,Daniel Ford,Joanna Gale,Stephanie Gibbs,Duncan C. Gilbert,Robert Hughes,Duncan B. McLaren,Jason F. Lester,A. Nikapota,Joe M. O'Sullivan,Joe M. O'Sullivan,Omi Parikh,Clive Peedell,Andrew Protheroe,Sarah Rudman,R. Shaffer,D. Sheehan,Matthew S. Simms,Narayanan Srihari,Räto T. Strebel,Santhanam Sundar,Shaun Tolan,David Tsang,Mohini Varughese,John Wagstaff,Mahesh K.B. Parmar,Nicholas D. James +55 more
TL;DR: This direct, randomised comparative analysis of two new treatment standards for hormone-naïve prostate cancer showed no evidence of a difference in overall or prostate cancer-specific survival, nor in other important outcomes such as symptomatic skeletal events.
Journal ArticleDOI
Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial
Nicholas D. James,Nicholas D. James,Melissa R. Spears,Noel W. Clarke,David P. Dearnaley,Malcolm David Mason,Chris Parker,A.W.S. Ritchie,J. Martin Russell,Francesca Schiavone,Gerhardt Attard,Johann S. de Bono,Alison Birtle,Daniel S. Engeler,Tony Elliott,David Matheson,Joe M. O'Sullivan,Delia Pudney,Narayanan Srihari,Jan Wallace,Jim Barber,Isabel Syndikus,Mahesh K. B. Parmar,Matthew R. Sydes +23 more
TL;DR: Survition for men entering the cohort with high-risk M0 disease was higher than anticipated at study inception and nonrandomized data were consistent with previous trials that support routine use of RT with HT in patients with N0M0 disease, suggesting that the benefits of RT extend to men with N+M1 disease.